News | Breast Imaging | January 04, 2021

SmartBreast Acquires Molecular Breast Imaging Assets from Dilon Technologies

Smart Breast Corporation (SmartBreast), a privately held company focused on breast cancer screening and detection, announced today that it has acquired certain molecular breast imaging (MBI) assets from Dilon Technologies, Inc. (Dilon) for an undisclosed amount.

January 4, 2021 — Smart Breast Corporation (SmartBreast), a privately held company focused on breast cancer screening and detection, announced today that it has acquired certain molecular breast imaging (MBI) assets from Dilon Technologies, Inc. (Dilon) for an undisclosed amount.

The assets acquired include the Dilon 6800 MBI scanner, the GammaLoc MBI-guided biopsy, a proprietary Variable-Angle Slant-Hole (VASH) collimator (designed by Thomas Jefferson National Accelerator Facility), 3D Tomographic software that uses the VASH collimator to render limited-angle molecular breast tomography (MBT), and acquisition and analysis software for these systems. Assets also include all inventory, designs, manufacturing tools and instructions, 3 registered trademarks, 4 patents covering the D6800 and GammaLoc technologies, 2 patents for the VASH collimator exclusively licensed from Jefferson Science Associates and 2 FDA 510(k) pre-market clearances as well as regulatory registrations in multiple countries.

The D6800 is an FDA-cleared compact, mobile scanner that is also FDA-cleared for MBI-guided biopsy of suspected breast cancers and has installations at 176 sites in more than 10 countries. SmartBreast intends to continue to manufacture, market and distribute the D6800 MBI scanner with GammaLoc.

MBI saves lives by detecting breast cancer earlier in women with dense breasts, who comprise up to 40% of American, European and African women and 70% of Asian women. Mammography fails to detect more than 50% of early-stage cancers in dense breasts. MBI sees through dense breast tissue and is able to find cancer between 3 and 4 times more often than mammography alone in multiple published studies including 1,000's of patients from the Mayo Clinic and others.

SmartBreast will utilize a global network of distributors led by EVO WorldWide. SmartBreast Co-founder and CEO, James Hugg, Ph.D., stated that "MBI is a game-changer for breast cancer in dense breast. In published clinical studies mammography was reported to find 3.2 cancers in each 1,000 women with dense breasts. Adding MBI increased the number of cancers found to 12 per 1,000. SmartBreast will make MBI accessible to many more dense-breast women who are literally gambling with their lives by relying on annual mammograms alone."

Dilon Board Chair, Robert Moussa, said "We are excited to hand off the Dilon 6800 to SmartBreast. We have known the co-founders for many years and are confident that they will continually improve the technology and make it available to women worldwide."

For more information: www.smartbreast.com

Related Content

For years telehealth has danced at the edges of healthcare
Feature | Teleradiology | January 21, 2021 | By Jef Williams
All indications point to 2021 being the year of the return path of this boomerang event that sent us all in a differe
Steinberg Diagnostic Medical Imaging headquarters.

Steinberg Diagnostic Medical Imaging headquarters.

Sponsored Content | Case Study | Contrast Media Injectors | January 21, 2021
Steinberg Diagnostic Medical Imaging (SDMI) was founded 30 years a
Radiologists have recently taken on the role of activists and are tackling pressing issues in healthcare, including breast density

Getty Images

Feature | Women's Health | January 20, 2021 | By Fazila Seker, Ph.D.
Radiologists — who have long been professionals in the metaphorical and literal back-rooms of healthcare — have recen
The key trends Clinicians reviewing a COVID-19 patient's lung CT that reveals the severity of COVID-caused pneumonia. The impact of COVID on radiology was a major, over arching trend at  the 2020 Radiological Society of North America (RSNA) meeting. Getty Imagesbserved at 2020 Radiological Society of North America (RSNA) meeting all focused around COVID-19 (SARS-CoV-2) and the impact it has had on radiology. #RSNA #RSNA20 #RSNA2020

Clinicians reviewing a COVID-19 patient's lung CT that reveals the severity of COVID-caused pneumonia. The impact of COVID on radiology was a major, over arching trend at  the 2020 Radiological Society of North America (RSNA) meeting. Getty Images

Feature | RSNA | January 20, 2021 | By Melinda Taschetta-Millane and Dave Fornell
MRI Targeted biopsy is performed using cognitive fusion more easily with anatomical guidance based on the radiology report. MRI targets can be identified quickly in real-time along with micro-ultrasound targets, which may have been missed on MRI.

MRI Targeted biopsy is performed using cognitive fusion more easily with anatomical guidance based on the radiology report. MRI targets can be identified quickly in real-time along with micro-ultrasound targets, which may have been missed on MRI. Image courtesy of Exact Imaging

Feature | Prostate Cancer | January 20, 2021 | By Brian Wodlinger, Ph.D.
Historically when a patient had an elevated PSA (prostate specific antigen) test their urologist would take the next
An interview with Eric Liederman, M.D., MPH, Director of Medical Informatics for The Permanente Medical Group, in Kaiser Permanente’s Northern California Region, on the explosion of telemedicine in the COVID-19 era

Getty Images

Feature | Radiology Business | January 20, 2021 | By Melinda Taschetta-Millane
Vendor neutral archives enable a single, central location to store large volumes of radiology data, but now need to be able to house data from dozens of other departments with a wide array of data formats. This article originally ran as an introduction to the Vendor Neutral Archives comparison chart.
Feature | Vendor Neutral Archive (VNA) | January 20, 2021 | By Dave Fornell
Most radiologists and clinicians are not trained as...
According to a new research report1 on the contrast media injectors published by MarketsandMarkets, the market was estimated to be $1.3 billion in 2020 and projected to reach $1.9 billion by 2025, at a compound annual growth rate (CAGR) of 7.4 percent over 2020-2025.

The ulrich CTmotion

Feature | Contrast Media Injectors | January 20, 2021 | By Melinda Taschetta-Millane
According to a new...
Previously approved by FDA in the USA, MyLab X8 expands the reach of the MyLab Ultrasound Product Line with a fully featured premium imaging solution, integrating the latest technologies and delivering superior image quality without compromising workflow or efficiency.
News | Ultrasound Imaging | January 20, 2021
January 20, 2021 — Esaote North America announces that the...